Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:17 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma
NCT04762160 · Epizyme, Inc. · PHASE2 · terminated · last registry update 2024-03-25 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Decision to terminate EZH-1401 was solely due to company business decision.” | – | Registry record, Epizyme, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against EZH2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-03-11Results posted on the registry: Epizyme, Inc., Tazemetostat (NCT02601950)
- 2025-03-06Results posted on the registry: National Cancer Institute (NCI), Tazemetostat (NCT03348631)
- 2024-10-03Results posted on the registry: Epizyme, Inc., Tazemetostat (NCT02601937)
- 2024-08-26Results posted on the registry: Epizyme, Inc., Tazemetostat + Itraconazole (NCT04537715)
- 2024-02-21Also stopped (terminated): Washington University School of Medicine, Tazemetostat + Pembrolizumab (NCT04624113)
- 2023-09-22Also stopped (withdrawn): Edwin Posadas, MD, Tazverik (NCT05567679)
- 2023-08-15Also stopped (withdrawn): Epizyme, Inc., Tazemetostat + Tafasitamab (NCT05205252)
- 2023-08-04Results posted on the registry: Epizyme, Inc., Tazemetostat + Prednisolone (NCT01897571)
- 2023-07-07Also stopped (withdrawn): Jacob Soumerai, MD, TAZEMETOSTAT + Zandelisib (NCT05604417)
- 2023-05-31Also stopped (withdrawn): City of Hope Medical Center, Tazemetostat + Ublituximab (NCT05152459)
- 2023-05-18Also stopped (withdrawn): Dana-Farber Cancer Institute, Implantable Microdevice (IMD) (NCT05774886)
- 2023-04-27Results posted on the registry: National Cancer Institute (NCI), Tazemetostat (NCT03213665)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision